BlessingfortheBleederBevacizumabinHereditary.PDFVIP

CMR Rapid Release. Published online ahead of print March 25, 2014 as doi:10.3121/cmr.2013.1205 Case Report Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia * † Narendranath Epperla MD and William Hocking MD, FACP Author Affiliations: *Department of Internal Medicine, Marshfield Clinic, Marshfield Wisconsin, USA †Department of Hematology-Oncology, Marshfield Clinic, Marshfield, Wisconsin, USA Running short title: Bevacizumab in HHT Word count: 93 abstract; 1181 text; 16 references; 2 tables; 1 figure Corresponding Author: Narendranath Epperla, MD Received: October 2, 2013 Department of Internal Medicine Revised: December 13, 2013 Marshfield Clinic Accepted: December 17, 2103 1000 North Oak Avenue Marshfield, WI 54449 doi:10.3121/cmr.2013.1205 Tel: (715) 387-5501 E-mail: epperla.naren@marshfieldclinic.org Conflict of interest: The authors declare that they have no conflict of interest. Bevacizumab in HHT Page 1 Copyright 2014 Marshfield Clinic / Marshfield Clinic Research Foundation Copyright 2014 by Marshfield Clinic. Epperla and Hocking doi:10.3121/cmr.2013.1205 Abstract Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by uncontrolled multisystem angiogenesis with epistaxis, gast